Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAYBREAK: Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in wAMD
NCT06556368Phase 3Active, not recruiting
- Sponsor
- Kodiak Sciences
- Start
- Aug 2024
- Primary completion
- Sep 2026
- Modality
- Biodegradable Polymers, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
A Phase 3 trial of tarcocimab tedromer, tabirafusp tedromer in exudative macular degeneration, sponsored by Kodiak Sciences. Started Aug 2024; status: active, not recruiting.
02
Drugs
tarcocimab tedromertabirafusp tedromer
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT06556368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06556368.